Navigation Links
Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
Date:7/9/2008

MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Christopher Kurtz has joined the company as Vice President, Global Supply Chain and Sustainment Engineering. He will have primary responsibilities in the development and execution of Alexza's global supply chain strategy to support the commercialization of Alexza's pipeline of clinical product candidates. Alexza's lead program, AZ-004 (Staccato(R) loxapine) is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients.

Mr. Kurtz was most recently Vice President of Research and Development and Director, Pharmaceutical Manufacturing and Development for Novo Nordisk Delivery Technologies, Hayward, California. Prior to his tenure at Novo, Mr. Kurtz held positions as Senior Director, Process Engineering for ALZA Corporation, a division of Johnson and Johnson from January to June 2006. He was previously Director, Operations Engineering and Director Manufacturing Engineering for Nektar Therapeutics, San Carlos, California from January 2001 to January 2006 and also held previous positions at PowderJect Pharmaceuticals, PLC and Monsanto, Inc. Mr. Kurtz holds a Bachelor of Science degree in Chemical Engineering and Chemistry from University of Colorado at Boulder.

"We are very pleased to welcome Christopher to Alexza and as a member of our Executive Team," said Michael Simms, Senior Vice President, Operations and Manufacturing. "His broad experience in working with external manufacturing partners to develop, scale-up and launch drug delivery-based products will be instrumental as Alexza rapidly moves toward commercialization of its pipeline."

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development of the Company's product candidates, projected clinical trial enrollment and data reporting timelines, and safety of the Company's products and technologies. Any statement describing a product candidate or Alexza's goals, expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
2. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
3. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
4. Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
5. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
6. Pharmasset Joins Russell 3000 Index
7. Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
8. Signalife Announces AFL Joins NIH Education Program
9. Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVaults Board of Directors
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Loic Maurel Joins Exonhit Therapeutics to Become CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... of women’s health, primary care, and specialty education, announced today it has ... (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and is the ...
(Date:2/22/2017)... , Feb 22, 2017 Dublin ... the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, ... report to their offering. ... Global Biological Crop Protection Market is forecasted to ... The strong growth in biopesticide or biological crop protection market is ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma ... Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, ... Perkins joins Pennside after more than a decade with leading market research firm, ...
(Date:2/21/2017)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported ... December 31, 2016. SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed ... ... in fiscal 2016," said Andrew Morris , SQI,s President ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):